LOVAZA Drug Patent Profile

When do Lovaza patents expire, and when can generic versions of Lovaza launch?

Lovaza is a drug marketed by Waylis Therap and is included in one NDA.

The generic ingredient in LOVAZA is omega-3-acid ethyl esters. There are thirteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the omega-3-acid ethyl esters profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lovaza

A generic version of LOVAZA was approved as omega-3-acid ethyl esters by GLW on April 7^th, 2014.

Summary for LOVAZA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	7
Clinical Trials:	82
Patent Applications:	1,089
Drug Prices:	Drug price information for LOVAZA
What excipients (inactive ingredients) are in LOVAZA?	LOVAZA excipients list
DailyMed Link:	LOVAZA at DailyMed

See drug prices for LOVAZA

See drug sales revenues for LOVAZA

Recent Clinical Trials for LOVAZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Prisma Health-Midlands	Phase 2/Phase 3
H. Lee Moffitt Cancer Center and Research Institute	Phase 2
James and Esther King Biomedical Research Program	Phase 2

See all LOVAZA clinical trials

Pharmacology for LOVAZA

Drug Class

Omega-3 Fatty Acid

Paragraph IV (Patent) Challenges for LOVAZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LOVAZA	Capsules	omega-3-acid ethyl esters	1 g	021654	3	2008-11-10

US Patents and Regulatory Information for LOVAZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Waylis Therap	LOVAZA	omega-3-acid ethyl esters	CAPSULE;ORAL	021654-001	Nov 10, 2004	AB	RX	Yes	Yes

Expired US Patents for LOVAZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Waylis Therap	LOVAZA	omega-3-acid ethyl esters	CAPSULE;ORAL	021654-001	Nov 10, 2004	5,698,594
Waylis Therap	LOVAZA	omega-3-acid ethyl esters	CAPSULE;ORAL	021654-001	Nov 10, 2004	5,502,077
Waylis Therap	LOVAZA	omega-3-acid ethyl esters	CAPSULE;ORAL	021654-001	Nov 10, 2004	7,732,488

International Patents for LOVAZA

See the table below for patents covering LOVAZA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	3905538
Japan	H02104522	FATTY ACID COMPOSITION
China	1668728	A process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product

LOVAZA: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

LOVAZA (omega-3-acid ethyl esters) is a branded prescription product in a crowded but still structurally advantaged niche: patients who remain on fixed-dose, physician-directed therapy for hypertriglyceridemia. The market’s financial trajectory is shaped by (1) generic erosion of many branded cardiovascular and lipid categories, (2) ongoing competition from prescription and over-the-counter omega-3 formulations, (3) payer pressure tied to safety, dosing economics, and clinical differentiation, and (4) a long, late-cycle brand lifecycle where growth is generally constrained and revenue is driven by share maintenance and list-price discipline rather than pipeline replacement.

How is LOVAZA used in the lipid/HTG market?

LOVAZA is prescribed for hypertriglyceridemia. Commercial demand is driven by four buckets:

1) Clinician diagnosis intensity
Hypertriglyceridemia management often follows guideline-based lipid workups. When testing volumes rise and treatment thresholds tighten, prescription demand for triglyceride-lowering products tends to hold up.

2) Therapeutic switching within omega-3 classes
Patients can switch among branded and generic omega-3 products depending on payer coverage, copays, and perceived clinical value.

3) Access and coverage rules
Formularies and prior authorization protocols determine whether LOVAZA is preferred, covered with restrictions, or substituted with lower-cost alternatives.

4) Dosing economics and adherence
Omega-3 regimens can create tolerability and pill-burden considerations, which affect persistence and renewal.

What market forces drive revenue volatility and share?

LOVAZA’s market dynamics are not determined by a single driver. The revenue path reflects a mix of pricing and mix shifts plus sustained competition.

1) Generic substitution and class spillover

Across lipid therapy, payers exert pressure to substitute lower-cost options once generics or therapeutically substitutable alternatives are available. Omega-3 products have had multiple entry points from generic and branded competitors, so LOVAZA’s key risk is share erosion through cost-based formulary decisions.

2) Payer stewardship and protocol design

Payers increasingly tie coverage to:

• triglyceride severity thresholds,
• documented treatment intent (for example, diet plus drug),
• step edits requiring alternative omega-3 products, and
• safety monitoring expectations.

Those levers compress net pricing and can shift volume to competitors with better formulary positioning.

3) Competitive differentiation by product form and dosing

Even when competitors are “omega-3,” their dosing regimen and pill burden differ. That creates head-to-head switching behavior when payers implement pharmacy benefit incentives or when clinicians prefer a regimen aligned with patient tolerability.

4) Late-cycle brand economics

LOVAZA is a mature product. Mature branded products typically grow slowly or decline gradually unless there is a material coverage gain, new clinical narrative, or a pricing event that increases net revenue faster than volume losses.

How has LOVAZA’s financial trajectory evolved?

LOVAZA’s financial trajectory has followed a common pattern for long-lived prescription brands:

• early stabilization after major competitive entries,
• gradual net revenue compression as substitution intensifies,
• periodic stabilization when list price and contracting preserve net price,
• revenue declines when coverage deterioration outweighs pricing gains.

For business planning, the actionable framing is: LOVAZA revenue is mainly a function of (1) persistence of the current treated population and (2) how aggressively payers steer to other omega-3 products, including lower-cost options.

What does the competitive landscape imply for forward revenue?

LOVAZA sits in a market segment where competitors can compete on:

• rebate strength and formulary placement,
• dosing and tolerability,
• copay design,
• willingness to pursue preferred status with large commercial plans.

That means forward revenue is sensitive to payer negotiations and formulary updates more than to incremental clinical wins late in the product lifecycle.

Key market metrics that matter for LOVAZA unit economics

The revenue line is influenced by four drivers that change with each payer cycle:

Driver	How it moves revenue	What to watch operationally
Net price	Rebates and contracting decide whether list price translates into net	PBM contracting cycles, formulary tier placement, rebate offers
Covered share	Preferred status determines volume capture	Segment-by-segment formulary wins and losses
Switching behavior	Patients may switch based on cost and dosing	Claims-based persistence and time-to-switch
Adherence/persistence	Pill burden and tolerability affect refills	Refill rate trends, discontinuation patterns

Where does LOVAZA sit in payer decision trees?

A typical payer coverage pattern in omega-3 therapy includes:

• broad coverage for mild-to-moderate hypertriglyceridemia when drug budget allows, and
• restriction for higher-cost products when cheaper omega-3 options exist.

In practice, this pushes LOVAZA toward:

• maintenance of share in plans where it is already established, and
• incremental losses when plans update formularies in response to class affordability pressures.

Financial trajectory implications for 3 scenarios (management use)

Base case (most likely pattern for mature brands)

• Net revenue stays stable to slowly declines as volume is gradually lost to lower-cost options.
• Pricing and contracting partially offset volume erosion.

Downside (faster formulary deterioration)

• Larger share loss when payers shift preferred status away from LOVAZA.
• More restrictive step edits and prior authorization reduce accessible volume.

Upside (coverage gains or improved contracting)

• Rebate and tier position improvements restore covered share.
• Persistence improves due to stronger patient support or tolerability adherence.

Patent and regulatory cycle: what matters commercially

LOVAZA’s commercial future depends less on a near-term patent runway and more on how long branded differentiation can be defended in contracting and coverage. For late-cycle brands, “exclusivity” and regulatory barriers influence timing and the pace of substitution, but the dominant near-term financial lever remains payer access.

Actionable business read-through

For R&D and investment decision-making, LOVAZA is a case study in how mature branded niche therapies behave:

• revenue is primarily a function of payer positioning and persistence,
• competition pressure is continuous even without major clinical changes,
• “financial trajectory” is less about new uptake and more about access durability.

Key Takeaways

• LOVAZA’s market dynamics are driven by payer access, formulary tiering, and omega-3 class substitution, not by new demand creation typical of early lifecycle products.
• The financial trajectory follows a mature-brand pattern: gradual net revenue compression as lower-cost alternatives gain coverage.
• Forward performance hinges on contracting strength and covered share durability against prescription and generic omega-3 competitors.

FAQs

1) What is LOVAZA’s therapeutic positioning that supports demand?

LOVAZA is used for hypertriglyceridemia, with prescription demand linked to guideline-driven diagnosis and treatment persistence.

2) What most directly reduces LOVAZA net revenue?

Net revenue erosion typically comes from formulary tier downgrades, substitution to lower-cost omega-3 options, and rebate pressure that lowers net pricing.

3) Can LOVAZA grow in a mature omega-3 market?

Growth is usually limited; performance most often reflects share maintenance and persistence, with upside tied to payer contracting and coverage stability.

4) How does dosing and tolerability affect LOVAZA commercial outcomes?

Omega-3 dosing burden and patient tolerability influence refill behavior and discontinuation, which directly impact persistence and annual demand.

5) What should investors monitor to assess near-term trajectory?

Quarterly signals of covered share changes, net pricing versus list price, and claims persistence (switching and discontinuation) in major commercial and managed care segments.

---

References (APA)

[1] FDA. (n.d.). LOVAZA (omega-3-acid ethyl esters) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/